FDA's Off-Label Marketing Rules Take Hit In Amarin Fight
A New York federal judge on Friday ruled that Amarin Pharma Inc. has a constitutional right to make certain truthful and nonmisleading statements about off-label uses of omega-3 drug Vascepa, striking...To view the full article, register now.
Already a subscriber? Click here to view full article